BD Declares Quarterly Dividend as Commitment to Shareholders Continues

BD Board Declares Quarterly Dividend

Franklin Lakes, N.J., April 29, 2025 - Becton, Dickinson and Company (NYSE: BDX), a leading name in global medical technology, shared big news today. The company’s Board of Directors announced the declaration of a quarterly dividend of $1.04 per common share. This dividend is set to be paid out on June 30, 2025, to all shareholders who hold the stock as of June 9, 2025. With this, BD reaffirms its commitment to returning value to its shareholders.

This quarterly announcement comes with an indicated annual dividend rate of $4.16 per share, showcasing BD's strong financial performance and its consistent growth strategy. The decision to declare this dividend underscores the company's resilience and dedication to sustaining long-term shareholder value, particularly in an era marked by health challenges and rapid advancements in the medical sector.

BD operates as one of the largest global medical technology firms, significantly contributing to healthcare innovation. Their mission? To improve health around the world by advancing medical discoveries, diagnostics, and delivery of care. The company stands as a pillar of support for healthcare professionals through the development of innovative technologies, services, and solutions aimed at elevating patient care.

With a workforce of over 70,000 employees, BD remains devoted to enhancing the efficiency and safety of healthcare delivery. Their collaborative approach not only aids in clinical therapies but also empowers laboratory scientists to diagnose diseases with precision. BD’s efforts are instrumental in facilitating researchers' capabilities to innovate new diagnostics and therapeutics that drive healthcare improvements.

BD's commitment extends beyond profit maximization as it aligns with humanitarian goals. The organization collaborates closely with partners globally to tackle pressing health challenges, ultimately aspiring to improve outcomes, reduce costs, increase efficiencies, and expand access to healthcare.

In a recent statement, a company spokesperson emphasized the importance of this dividend as part of BD's strategy to balance growth with shareholder returns. The Board of Directors will continue to evaluate the company's performance and aims to uphold a robust dividend policy, as part of its broader commitment to stakeholders.

With the ongoing necessity for advanced healthcare solutions and the challenges presented in today's complex medical environment, BD's financial agility and commitment to dividends make it a notable player in the sector. Stakeholders can expect BD to keep pushing boundaries in healthcare technology while also offering steady returns to its investors.

For more about BD and its innovations, visit bd.com or connect on social platforms such as LinkedIn and Instagram, where the company actively engages with its community regarding health advancements.

This announcement could invigorate interest from both current investors and potential shareholders keen on entering a leading firm with not only a promising future but a rich heritage of improving health worldwide. Stay tuned for more updates from BD as they continue to make strides in the healthcare landscape.